Imidazole derivatives and their use as trpv4 inhibitors
A technology of base imidazole and drug, applied in the field of imidazole derivatives and their use as TRPV4 inhibitors, can solve the problems of uncontrolled inflammatory reaction in the lung and increased expression of TRPV4, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0104] Example 1: 10-(4-(4-(6-N,N-dimethylformamido-8-isopropylamino-9H-purin-9-yl)-piperidin-1-yl)- Phenyl)-9,9-dimethyl-9,10-dihydroacridine
[0105] Take 51mg (0.14mmol) 4-(6-N, N-dimethylformamido-8-isopropylamino-9H-purin-9-yl) piperidine hydrochloride, 51mg (0.14mmol) 10- (4-Bromophenyl)-9,9-dimethyl-9,10-dihydroacridine, 3.1mg (0.01mmol) palladium acetate, 8.2mg (0.03mmol) 2-(di-tert-butylphosphine) Benzene, 135mg (0.42mmol) cesium carbonate dissolved in 1ml 1,4-dioxane, under nitrogen protection, heated to 100°C, stirred for 18 hours, stopped the reaction, filtered with diatomaceous earth, collected the filtrate, evaporated the solvent under reduced pressure , 60 mg of the product was isolated by column chromatography (yield 70.4%). 1 H-NMR (CHLOROFORM-D, 400MHz): δ8.62 (s, 1H), 7.44 (dd, J=7.6, 1.6Hz, 2H), 7.20 (q, J=8.9Hz, 4H), 6.94 (dtd, J=25.4, 7.3, 1.5Hz, 4H), 6.33(dd, J=8.1, 1.1Hz, 2H), 4.58(br, 1H), 4.39(m, 2H), 3.99(d, J=12.1Hz, 2H ), 3.20(s, 3H), 3.11-2.97...
Embodiment 2
[0106] Example 2: 10-(4-(4-(6-chloro-8-isopropylamino-9H-purin-9-yl)-piperidin-1-yl)-phenyl)-9,9-di Methyl-9,10-dihydroacridine
[0107] The method is the same as in Example 1, 45mg (0.14mmol) 4-(6-chloro-8-isopropylamino-9H-purin-9-yl) piperidine hydrochloride and 51mg (0.14mmol) 10-(4-bromo Phenyl)-9,9-dimethyl-9,10-acridine was reacted to obtain 42 mg of white solid (53.7% yield). 1 H-NMR (d-DMSO, 400MHz): δ8.27(s, 1H), 7.44(dd, J=7.8, 1.5Hz, 2H), 7.36(d, J=7.5Hz, 1H), 7.25(d, J=9.0Hz, 2H), 7.15(d, J=9.0Hz, 2H), 6.99-6.93(m, 2H), 6.89-6.83(m, 2H), 6.22(dd, J=8.2, 1.2Hz, 2H ), 4.54(m, 1H), 4.23-4.14(m, 1H), 4.00(d, J=12.4Hz, 2H), 2.96-2.73(m, 4H), 1.87(d, J=13.3Hz, 2H) , 1.58(s, 6H), 1.27(d, J=6.6Hz, 6H); ESI-MS(m / z): 578.28[M+H] +
Embodiment 3
[0108] Example 3: 10-(4-(4-(2-isopropylamino-5-methanesulfonyl-1H-benzimidazol-1-yl)-piperidin-1-yl)-phenyl)-9 , 9-Dimethyl-9,10-dihydroacridine
[0109] The method is the same as in Example 1, 80mg (0.21mmol) 4-(2-isopropylamino-5-methylsulfonyl-1H-benzimidazol-1-yl) piperidine hydrochloride and 78mg (0.21mmol) 10- (4-Bromophenyl)-9,9-dimethyl-9,10-dihydroacridine was reacted to obtain 76 mg of white solid (57.4% yield). 1 H-NMR (d-DMSO, 400MHz): δ8.01 (d, J=1.7Hz, 1H), 7.57 (dd, J=8.4, 1.7Hz, 1H), 7.38 (d, J=8.7Hz, 2H) , 7.34(d, J=8.4Hz, 1H), 6.97(d, J=8.8Hz, 2H), 4.41(br, 1H), 4.28(dq, J=13.2, 6.5Hz, 1H), 4.11(t, J=12.2 Hz, 1H), 3.87(d, J=12.7Hz, 2H), 3.04(s, 3H), 2.92(t, J=11.7Hz, 2H), 2.54 (qd, J=12.4, 3.8Hz, 2H), 1.98(d, J=10.3Hz, 2H), 1.71(s, 6H), 1.35(d, J=6.4Hz, 6H); ESI-MS(m / z): 620.31[M+H] +
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


